Skip to content
← All case studies
Oral peptide DTC · regulated

Nexum

Nexum is where we proved the paid-acquisition + compliance discipline at scale. Months of paid acquisition in a vertical where 30% of brands lose their accounts in year 1 — and we didn't.

0
Account suspensions
Below
CAC vs benchmark
<24h
Policy flag resolution
Before

What the setup looked like.

Nexum launched in 2026 selling oral peptide protocols. Same FDA/FTC constraints as Bio Prime plus stricter platform rules on Meta and Google. Two prior similar brands had been suspended on Meta within 3 months of launch.

What we installed
Phase 01 — Ad creative pre-screened
Every variant ran through 3 compliance gates before submission to Meta. No 'guaranteed results' or medical-claim language.
Phase 02 — Landing page parity
Landing page claims matched ad claims word-for-word. Most peptide brand suspensions trigger on creative/landing mismatch.
Phase 03 — Single-offer tests
We didn't run 12 ad sets. We ran 4 audience splits against 1 creative. Less noise to Meta's algorithm.
Phase 04 — Daily account-health monitoring
Ad Account Monitor agent watched for CPC spikes, policy flags, conversion drops. Alerted within hours, not days.
Phase 05 — Dead-lead re-engagement
DTC-tuned (14-day timing curve, not 90).
The numbers

What moved.

KPI
Before
After
Delta
Account suspensions
Industry: 30%
0
Survival is the metric
CAC
Industry: high
Below benchmark
Compliance + creative discipline
CPC volatility
Industry: 25%+
Low
Less Meta-algo confusion
The lesson

Most 'ad agencies' treat compliance as a copy-edit pass after creative is done. That's how brands get suspended. We treat compliance as a creative constraint at the moment of writing.

Operator's own brand (NOT a Thresia client — proof of paid acquisition system in regulated DTC). Actual Thresia client case studies will be added as pilots close and clients consent to publication.

Want this for your clinic?

Book a 15-min call →